febuxostat sandoz 80 mg film-coat. tabl.
sandoz sa-nv - febuxostat hemihydrate 82,28 mg - eq. febuxostat 80 mg - film-coated tablet - 80 mg - febuxostat hemihydrate 82.28 mg - febuxostat
febuxostat sandoz 120 mg film-coat. tabl.
sandoz sa-nv - febuxostat hemihydrate 123,42 mg - eq. febuxostat 120 mg - film-coated tablet - 120 mg - febuxostat hemihydrate 123.42 mg - febuxostat
febuxostat teva 120 mg film-coat. tabl.
teva pharma belgium sa-nv - febuxostat hemihydrate 123,42 mg - eq. febuxostat 120 mg - film-coated tablet - 120 mg - febuxostat hemihydrate 123.42 mg - febuxostat
febuxostat teva 80 mg film-coat. tabl.
teva pharma belgium sa-nv - febuxostat hemihydrate 82,28 mg - eq. febuxostat 80 mg - film-coated tablet - 80 mg - febuxostat hemihydrate 82.28 mg - febuxostat
febuxostat teva 120 mg film-coat. tabl.
teva pharma belgium sa-nv - febuxostat hemihydrate 123,42 mg - eq. febuxostat 120 mg - film-coated tablet - 120 mg - febuxostat hemihydrate 123.42 mg - febuxostat
febuxostat teva 80 mg film-coat. tabl.
teva pharma belgium sa-nv - febuxostat hemihydrate 82,28 mg - eq. febuxostat 80 mg - film-coated tablet - 80 mg - febuxostat hemihydrate 82.28 mg - febuxostat
febuxostat tablet, film coated
indoco remedies limited - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. for the safe and effective use of allopurinol, see allopurinol prescribing information. limitations of use : febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia. febuxostat tablets are contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with febuxostat tablets use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40
febuxostat tablet, film coated
msn laboratories private limited - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. limitations of use: febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia. febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with febuxostat use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (mrhd). no adve
febuxostat tablet, film coated
novadoz pharmaceuticals llc - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. limitations of use: febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia. febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with febuxostat use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (mrhd). no adve
febuxostat tablet, film coated
aphena pharma solutions - tennessee, llc - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. for the safe and effective use of allopurinol, see allopurinol prescribing information. limitations of use: febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia. febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with febuxostat use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 an